Search

everythinglearnresearchcommunity

for

Search:↓

A 15-year-old boy's severe scalp condition improved significantly with adalimumab and baricitinib treatment.

Cancer treatments can cause skin-related side effects that may affect patient quality of life and require changes in treatment.

Total glucosides of paeony can help treat skin conditions but need more research for clinical use.

Some treatments for severe hair loss work but often have side effects, with baricitinib showing the most promise.

Hair analysis is better than urine and blood for detecting past drug use.

The document concludes that treatments for cicatricial alopecia are not well-supported by evidence, but hair transplantation shows more predictable and satisfactory results.

Hidradenitis suppurativa is a chronic skin condition more common in women, linked to genetics and lifestyle factors, and associated with various other health issues.

Bupropion causes more hair loss than other antidepressants, with paroxetine causing the least.

Adalimumab is the most effective treatment for severe hidradenitis suppurativa, but more research is needed to improve treatment options.

Treating melasma in men is difficult, especially for the deeper skin layers, and may need more than just topical treatments.

The document concludes that the skin is a complex organ providing protection, sensation, and healing, with challenges in treating conditions like itchiness.

Rituximab can cause skin issues, but baricitinib may help improve them.

Tralokinumab for atopic dermatitis may cause eye issues and skin reactions, needing careful monitoring.

Children with alopecia areata often have vitiligo, allergic asthma, ADHD, and low vitamin B12 and ferritin levels.

Personalized treatments for hair loss focus on specific genetic and biological pathways.

Autologous platelet concentrates help heal and regenerate dental tissues.

Baseline severity and relapse history affect alopecia areata treatment and recurrence.

Gut microbiota changes might play a role in alopecia areata, and microbiome-targeted treatments show promise.

Baricitinib is effective and safe for treating severe alopecia areata.

Dissolving microneedles offer efficient, minimally invasive drug delivery through the skin.

Rhupus is a complex syndrome that is hard to diagnose due to unclear clinical criteria.

Dianabol boosts muscle growth but has serious health risks and legal issues.

Comprehensive screening for infections is crucial before starting JAK inhibitors in alopecia areata patients.

The mTOR signaling pathway is crucial for hair health and targeting it may lead to new hair loss treatments.

Alopecia areata is a hair loss condition caused by immune factors and can be treated with JAK inhibitors.

The Middle East and Africa need better data, treatment consensus, and support for Alopecia Areata.

Chemotherapy often causes hair loss in cancer patients, affecting their mental health, but scalp cooling can help prevent it.

Patients with a specific genetic variant have more severe alopecia areata and higher recurrence rates.